Soleus Capital Management
Latest statistics and disclosures from Soleus Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TGTX, IOVA, UTHR, NRIX, EDAP, and represent 22.32% of Soleus Capital Management's stock portfolio.
- Added to shares of these 10 stocks: TERN (+$34M), IOVA (+$32M), PRAX (+$21M), NRIX (+$20M), ELVN (+$18M), ALNY (+$17M), TXG (+$14M), EOLS (+$11M), MRUS (+$11M), ALEC (+$10M).
- Started 26 new stock positions in DYN, HIMS, EXAS, PODD, TERN, KIDS, MDXG, ALNY, RIGL, GMED.
- Reduced shares in these 10 stocks: , TEVA (-$47M), UTHR (-$38M), WGS (-$18M), , , Rigel Pharmaceuticals (-$14M), IRMD (-$11M), HUM (-$10M), NVCR (-$10M).
- Sold out of its positions in FOLD, ANNX, APGE, ARQT, BIIB, CMPS, DNLI, DNTH, HCA, Inhibrx.
- Soleus Capital Management was a net seller of stock by $-122M.
- Soleus Capital Management has $1.1B in assets under management (AUM), dropping by -15.84%.
- Central Index Key (CIK): 0001802630
Tip: Access up to 7 years of quarterly data
Positions held by Soleus Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Soleus Capital Management
Soleus Capital Management holds 92 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Tg Therapeutics (TGTX) | 5.7 | $65M | +15% | 3.6M | 17.79 |
|
| Iovance Biotherapeutics (IOVA) | 5.3 | $61M | +115% | 7.5M | 8.02 |
|
| United Therapeutics Corporation (UTHR) | 4.0 | $45M | -45% | 142k | 318.55 |
|
| Nurix Therapeutics (NRIX) | 3.8 | $43M | +84% | 2.1M | 20.87 |
|
| Edap Tms S A Sponsored Adr (EDAP) | 3.5 | $40M | 7.3M | 5.44 |
|
|
| Terns Pharmaceuticals (TERN) | 3.0 | $34M | NEW | 4.9M | 6.81 |
|
| Revolution Medicines (RVMD) | 2.9 | $33M | +17% | 856k | 38.81 |
|
| SurModics (SRDX) | 2.9 | $33M | -2% | 782k | 42.04 |
|
| Organogenesis Hldgs (ORGO) | 2.8 | $32M | +20% | 12M | 2.80 |
|
| Jasper Therapeutics Com New (JSPR) | 2.6 | $29M | +7% | 1.3M | 22.70 |
|
| Ideaya Biosciences (IDYA) | 2.1 | $24M | +30% | 694k | 35.11 |
|
| Axogen (AXGN) | 2.1 | $24M | +6% | 3.3M | 7.24 |
|
| Krystal Biotech (KRYS) | 2.0 | $23M | +49% | 126k | 183.64 |
|
| Merus N V (MRUS) | 2.0 | $22M | +92% | 376k | 59.17 |
|
| Penumbra (PEN) | 2.0 | $22M | +44% | 124k | 179.97 |
|
| Essa Pharma Com New (EPIX) | 2.0 | $22M | +17% | 4.2M | 5.26 |
|
| Praxis Precision Medicines I Com New (PRAX) | 1.9 | $22M | +1330% | 533k | 41.36 |
|
| Celcuity (CELC) | 1.7 | $20M | -30% | 1.2M | 16.38 |
|
| Inari Medical Ord (NARI) | 1.7 | $20M | +47% | 408k | 48.15 |
|
| Beigene Sponsored Adr (BGNE) | 1.7 | $20M | -7% | 138k | 142.67 |
|
| C4 Therapeutics Com Stk (CCCC) | 1.7 | $19M | +64% | 4.1M | 4.62 |
|
| Castle Biosciences (CSTL) | 1.6 | $19M | +17% | 854k | 21.77 |
|
| Neuropace (NPCE) | 1.6 | $18M | 2.4M | 7.56 |
|
|
| Enliven Therapeutics (ELVN) | 1.6 | $18M | NEW | 769k | 23.37 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.5 | $17M | NEW | 72k | 243.00 |
|
| Syndax Pharmaceuticals (SNDX) | 1.5 | $17M | +123% | 827k | 20.53 |
|
| Humana (HUM) | 1.5 | $17M | -38% | 44k | 373.65 |
|
| GSK Sponsored Adr (GSK) | 1.4 | $16M | +30% | 415k | 38.50 |
|
| Treace Med Concepts (TMCI) | 1.4 | $16M | +75% | 2.4M | 6.65 |
|
| Vaxcyte (PCVX) | 1.2 | $14M | -10% | 185k | 75.51 |
|
| 10x Genomics Cl A Com (TXG) | 1.2 | $14M | NEW | 719k | 19.45 |
|
| Cg Oncology (CGON) | 1.2 | $13M | +94% | 425k | 31.57 |
|
| Nuvalent Inc-a (NUVL) | 1.1 | $13M | +32% | 172k | 75.86 |
|
| Evolus (EOLS) | 1.1 | $13M | +620% | 1.2M | 10.85 |
|
| Enanta Pharmaceuticals (ENTA) | 0.9 | $10M | +37% | 800k | 12.97 |
|
| Alector (ALEC) | 0.9 | $10M | NEW | 2.2M | 4.54 |
|
| Keros Therapeutics (KROS) | 0.9 | $10M | -19% | 222k | 45.70 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 0.8 | $9.5M | -83% | 587k | 16.25 |
|
| Arcellx Common Stock (ACLX) | 0.8 | $9.4M | +13% | 171k | 55.19 |
|
| Biodesix (BDSX) | 0.8 | $9.4M | NEW | 6.1M | 1.53 |
|
| Tango Therapeutics (TNGX) | 0.8 | $9.0M | -22% | 1.0M | 8.58 |
|
| Orthopediatrics Corp. (KIDS) | 0.8 | $8.9M | NEW | 310k | 28.76 |
|
| Rigel Pharmaceuticals (RIGL) | 0.8 | $8.6M | NEW | 1.0M | 8.22 |
|
| Bausch Health Companies (BHC) | 0.7 | $8.4M | +80% | 1.2M | 6.97 |
|
| Immunic (IMUX) | 0.7 | $8.1M | 7.3M | 1.11 |
|
|
| Y Mabs Therapeutics (YMAB) | 0.7 | $7.8M | +13% | 648k | 12.08 |
|
| Engene Holdings (ENGN) | 0.7 | $7.5M | 800k | 9.43 |
|
|
| Pharvaris N V (PHVS) | 0.7 | $7.5M | 399k | 18.80 |
|
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 0.6 | $7.2M | NEW | 509k | 14.06 |
|
| Dyne Therapeutics (DYN) | 0.6 | $7.1M | NEW | 201k | 35.29 |
|
| CVRX (CVRX) | 0.6 | $7.0M | +1110% | 587k | 11.99 |
|
| Insmed Com Par $.01 (INSM) | 0.6 | $6.9M | -59% | 103k | 67.00 |
|
| Hims & Hers Health Com Cl A (HIMS) | 0.6 | $6.7M | NEW | 333k | 20.19 |
|
| Theratechnologies Com New (THTX) | 0.6 | $6.7M | 4.8M | 1.40 |
|
|
| Immunovant (IMVT) | 0.6 | $6.7M | -4% | 252k | 26.40 |
|
| Adaptive Biotechnologies Cor (ADPT) | 0.5 | $6.2M | NEW | 1.7M | 3.62 |
|
| Applied Therapeutics (APLT) | 0.5 | $5.9M | -18% | 1.3M | 4.67 |
|
| Globus Med Cl A (GMED) | 0.5 | $5.9M | NEW | 86k | 68.49 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 0.5 | $5.8M | NEW | 54k | 106.73 |
|
| Bioatla (BCAB) | 0.5 | $5.3M | -4% | 3.9M | 1.37 |
|
| Erasca (ERAS) | 0.4 | $5.1M | NEW | 2.2M | 2.36 |
|
| Verastem Com New (VSTM) | 0.4 | $5.0M | +7% | 1.7M | 2.98 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.4 | $4.5M | -52% | 1.2M | 3.60 |
|
| Iradimed (IRMD) | 0.4 | $4.5M | -71% | 102k | 43.94 |
|
| Miragen Therapeutics (VRDN) | 0.4 | $4.4M | 340k | 13.01 |
|
|
| EXACT Sciences Corporation (EXAS) | 0.3 | $3.9M | NEW | 92k | 42.25 |
|
| Insulet Corporation (PODD) | 0.3 | $3.8M | NEW | 19k | 201.80 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.3 | $3.7M | NEW | 200k | 18.67 |
|
| Inspiremd (NSPR) | 0.3 | $3.4M | 1.4M | 2.50 |
|
|
| Calcimedica Com New (CALC) | 0.3 | $3.1M | 784k | 3.96 |
|
|
| The Beauty Health Company Com Cl A (SKIN) | 0.3 | $3.1M | +843% | 1.6M | 1.92 |
|
| Sanofi Sponsored Adr (SNY) | 0.3 | $3.0M | NEW | 63k | 48.52 |
|
| Fate Therapeutics (FATE) | 0.3 | $2.9M | 870k | 3.28 |
|
|
| X4 Pharmaceuticals (XFOR) | 0.2 | $2.3M | -11% | 4.1M | 0.58 |
|
| Olema Pharmaceuticals (OLMA) | 0.2 | $2.3M | -67% | 217k | 10.82 |
|
| Janux Therapeutics (JANX) | 0.2 | $2.3M | -64% | 56k | 41.89 |
|
| 4d Molecular Therapeutics In (FDMT) | 0.2 | $2.3M | -44% | 109k | 20.99 |
|
| Genedx Holdings Corp Com Cl A (WGS) | 0.2 | $2.3M | -88% | 87k | 26.14 |
|
| Cervomed (CRVO) | 0.2 | $2.2M | 127k | 17.12 |
|
|
| Avita Therapeutics (RCEL) | 0.2 | $2.1M | +256% | 267k | 7.92 |
|
| Novocure Ord Shs (NVCR) | 0.2 | $1.9M | -84% | 109k | 17.13 |
|
| Inhibrx Biosciences (INBX) | 0.1 | $1.3M | NEW | 89k | 14.17 |
|
| Oric Pharmaceuticals (ORIC) | 0.1 | $1.2M | -61% | 163k | 7.07 |
|
| Adverum Biotechnologies Com New (ADVM) | 0.1 | $1.0M | NEW | 147k | 6.86 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.1 | $682k | NEW | 15k | 45.44 |
|
| Orthofix Medical (OFIX) | 0.1 | $676k | NEW | 51k | 13.26 |
|
| MiMedx (MDXG) | 0.1 | $574k | NEW | 83k | 6.93 |
|
| Aadi Bioscience (AADI) | 0.0 | $487k | NEW | 333k | 1.46 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.0 | $476k | -84% | 24k | 20.24 |
|
| Natera (NTRA) | 0.0 | $390k | -95% | 3.6k | 108.29 |
|
| Io Biotech (IOBT) | 0.0 | $225k | NEW | 193k | 1.17 |
|
| Xeris Pharmaceuticals (XERS) | 0.0 | $140k | 62k | 2.25 |
|
Past Filings by Soleus Capital Management
SEC 13F filings are viewable for Soleus Capital Management going back to 2019
- Soleus Capital Management 2024 Q2 filed Aug. 14, 2024
- Soleus Capital Management 2024 Q1 filed May 15, 2024
- Soleus Capital Management 2023 Q4 filed Feb. 14, 2024
- Soleus Capital Management 2023 Q3 filed Nov. 14, 2023
- Soleus Capital Management 2023 Q2 filed Aug. 14, 2023
- Soleus Capital Management 2023 Q1 filed May 15, 2023
- Soleus Capital Management 2022 Q4 filed Feb. 14, 2023
- Soleus Capital Management 2022 Q3 filed Nov. 14, 2022
- Soleus Capital Management 2022 Q2 filed Aug. 15, 2022
- Soleus Capital Management 2022 Q1 filed May 16, 2022
- Soleus Capital Management 2021 Q4 filed Feb. 14, 2022
- Soleus Capital Management 2021 Q3 filed Nov. 15, 2021
- Soleus Capital Management 2021 Q2 filed Aug. 16, 2021
- Soleus Capital Management 2021 Q1 filed May 17, 2021
- Soleus Capital Management 2020 Q4 restated filed April 29, 2021
- Soleus Capital Management 2020 Q4 filed Feb. 16, 2021